1. Home
  2. AVDL vs GRC Comparison

AVDL vs GRC Comparison

Compare AVDL & GRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • GRC
  • Stock Information
  • Founded
  • AVDL 2015
  • GRC 1933
  • Country
  • AVDL Ireland
  • GRC United States
  • Employees
  • AVDL N/A
  • GRC N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • GRC Fluid Controls
  • Sector
  • AVDL Health Care
  • GRC Industrials
  • Exchange
  • AVDL Nasdaq
  • GRC Nasdaq
  • Market Cap
  • AVDL 900.2M
  • GRC 1.0B
  • IPO Year
  • AVDL 1996
  • GRC N/A
  • Fundamental
  • Price
  • AVDL $9.54
  • GRC $37.39
  • Analyst Decision
  • AVDL Strong Buy
  • GRC
  • Analyst Count
  • AVDL 6
  • GRC 0
  • Target Price
  • AVDL $18.17
  • GRC N/A
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • GRC 54.6K
  • Earning Date
  • AVDL 08-07-2025
  • GRC 07-25-2025
  • Dividend Yield
  • AVDL N/A
  • GRC 1.94%
  • EPS Growth
  • AVDL N/A
  • GRC 21.97
  • EPS
  • AVDL N/A
  • GRC 1.69
  • Revenue
  • AVDL $194,450,000.00
  • GRC $664,347,000.00
  • Revenue This Year
  • AVDL $56.88
  • GRC $4.50
  • Revenue Next Year
  • AVDL $29.81
  • GRC $4.50
  • P/E Ratio
  • AVDL N/A
  • GRC $22.58
  • Revenue Growth
  • AVDL 252.64
  • GRC 0.92
  • 52 Week Low
  • AVDL $6.38
  • GRC $30.87
  • 52 Week High
  • AVDL $17.30
  • GRC $43.79
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 56.42
  • GRC 51.75
  • Support Level
  • AVDL $8.74
  • GRC $37.75
  • Resistance Level
  • AVDL $9.56
  • GRC $38.53
  • Average True Range (ATR)
  • AVDL 0.39
  • GRC 0.78
  • MACD
  • AVDL 0.04
  • GRC 0.11
  • Stochastic Oscillator
  • AVDL 81.92
  • GRC 62.12

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

Share on Social Networks: